NewTimeSpace News: YONGDA AUTO (03669.HK) plans to issue in total 73.16 million shares.
Lvji Technology announced on July 15 that its wholly-owned subsidiary Lvji International Travel entered into a corporate loan contract with Guangzhou Rural Commercial Bank Huangpu Branch for RMB10 million, with a term of 12 months (July 10, 2026 to July 10, 2027), a fixed annual interest rate of 3.2% (based on one-year LPR plus 20 basis points), funds for working capital, and guarantee by mortgage and guarantee. The Board considers the loan provides additional funds for daily operations with terms determined through fair negotiation. Rural Commercial Bank is an independent third party, and the loan contract does not constitute a notifiable or connected transaction.
Xiamen Jihong entered into a placing agreement on July 16 with Guotai Junan Securities, China Merchants Securities and Lico Securities to place up to 9.3715 million new H-shares at HK$12.24 per share (approximately 17.02% discount to the last trading day closing price of HK$14.75), with estimated net proceeds of approximately HK$112.8 million. The Placing Shares represent approximately 13.80% of existing H-shares and 2.14% of total issued shares, to be conducted under the general mandate without further shareholders' approval. Proceeds allocation: 80% for global expansion of cross-border social e-commerce (Europe and Middle East overseas expansion HK$45.1 million, self-developed brands HK$33.8 million, Giikin system R&D upgrade HK$11.3 million), 10% for supply chain optimization and paper-based FMCG packaging business expansion, and 10% for working capital. Expected completion date is July 23, 2026, with a 45-day lock-up commitment post-completion.
LongBio Pharma announced on July 16 that the Board has resolved to propose the adoption of the H-share Share Option Scheme and H-share Share Incentive Scheme, aiming to establish a long-term incentive mechanism, attract and retain core talent, and drive commercial transformation and value enhancement. The plan cap shall not exceed 10% of the total issued shares (excluding treasury shares). The H-share Share Option Scheme will be satisfied through issuing new H-shares or transferring treasury shares, while the H-share Share Incentive Scheme will be satisfied through trustee purchases of new H-shares, secondary market purchases, or treasury shares. Both schemes are subject to approval by special resolution at the EGM and the Stock Exchange listing committee.
IngDan announced on July 16 that the Group has completed its strategic upgrade from an AI hardware distributor to a vertical AI Token factory operator, having cumulatively signed intent service orders exceeding US$1 billion with customers including global tier-one cloud service providers, embodied intelligence companies and AI model companies. The Group has established a vertical industry Token computing power scheduling platform with a revenue sharing model and dual-track infrastructure deployment. The Board believes the Group has established a first-mover advantage in the vertical AI computing power track and will develop Token operation services as its second growth curve. The intent orders are not yet signed contracts, and actual revenue recognition will depend on service agreement execution and business conditions.
XIAOMI-W(01810.HK) will spend HKD 100.69 million to repurchase 3.9 million shares on Jul 15, 2026 .
NewTimeSpace News: Marketingforce Managementannounced on 15 July that the Group expects its total revenue for the six months ended 30 June 2026 to range from approximately RMB 1.858 billion to RMB 2.054 billion, representing a year-on-year growth of 100% to 121%. Revenue generated from AI application business is projected to hit RMB 1.068 billion to RMB 1.180 billion, up 112% to 134% year on year.
NewTimeSpace News: Hengrui Pharmaceuticalsannounced on July 15 that its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. has obtained the Clinical Trial Approval Notice for Concentrated Solution for Injection HRS-8829 issued and approved by the National Medical Products Administration (NMPA).
NewTimeSpace News: MicroPort Scientific announced on 15 July that its subsidiary Suzhou MicroPort Orthopedics (Group) Co., Limited has entered into a letter of intent with Beijing Tinavi Medical Technology Co., Ltd. Tinavi intends to acquire the controlling equity interest in MicroPort Orthopedics (Shanghai) Co., Ltd. from Suzhou MicroPort and other shareholders of the target company, with the consideration to be settled via the issuance of new shares by Tinavi.
NewTimeSpace News: Renrui Human Resources announced on 15 July that Ms. Wang Xinjie, Non-executive Director, has resigned with effect from 15 July. On the same day, Ms. Gao Yunjie nominated by Beyondsoft was appointed as a Non-executive Director.
NewTimeSpace News: Ubox Online announced on 15 July that the Hong Kong Stock Exchange (HKEX) has approved the conversion, listing and trading of 40,671,930 domestic shares into H shares on 9 July 2026.
NewTimeSpace News: Chengdu Expressway announced on 15 July that Chengwenqiong Expressway Company, its wholly-owned subsidiary, entered into a YZ section procurement contract for precast concrete components with Chengdu Chengtou Urban Construction. The contracted price stands at around RMB 234 million (tax inclusive) for the Chengdu-Wenjiang-Qionglai Expressway Expansion Project.
NewTimeSpace News: On 15 July, Prinx Chengshan announced that Mr. Che Baozhen, Executive Director and Chief Executive Officer, will resign as CEO with effect from 1 August. On the same date, Mr. Jiang Xizhou, Executive Director and Chief Operating Officer, was appointed as President.
NewTimeSpace News: On 15 July, Fameglow Holdingsannounced that its indirectly wholly-owned subsidiary has signed a technology development agreement with Hongkong Sunseeker Technology Limited, entrusting the latter to build an anti-aging and health management platform based on AI models.
NewTimeSpace News: On 15 July, Zhongtai Futures announced that the Group expects its net profit attributable to shareholders for the six months ended 30 June 2026 to grow by approximately 190% to 210% compared with the same period in 2025.
NewTimeSpace News: On 15 July, InnoCare Pharma Limitedannounced that Soficitinib (ICP-332), a new-generation oral TYK2 inhibitor independently developed by the Company, successfully met the primary endpoint in its Phase III registrational clinical trial for the treatment of moderate-to-severe atopic dermatitis.
